Compare ADMA Biologics Inc (ADMA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Charles Schwab Corporation Common Stock — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Charles Schwab Corporation Common Stock trades at $101.8 (market cap $177.27B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 83.2× ADMA Biologics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SCHW | |
|---|---|---|
Market Cap | $2.13B | $177.27B |
Sector | Health | Financials |
52-Week High | $20.38 | $107.21 |
52-Week Low | $7.60 | $85.35 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Charles Schwab (SCHW) trades at $101.93, up 5.08% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with a 37.99% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.43 exceeding expectations. Recent news highlights retail trading growth and a new prediction market venture with Cboe, supporting positive sentiment.
Outlook remains favorable with a $120.38 analyst price target implying 18% upside, though overbought RSI signals near-term caution. Key risks include interest rate sensitivity and competitive pressures. Wall Street consensus is bullish with 58% buy ratings, reflecting confidence in Schwab's revenue diversification and asset growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
